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Abstract
The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin
lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage
IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have
been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to
improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their
prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic signif-
icance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients
underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these
patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS.
Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We
believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplan-
tation could explain the complete disappearance of the residual prognostic significance of the IPS.
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For several years, the most widely utilized risk stratification
tool for advanced Hodgkin’s lymphoma (HL) patients has
been the International Prognostic Score (IPS). It is a retrospec-
tively developed clinical model based on the outcome of about
1600 patients with advanced stage disease. A large majority of
these patients were treated before 1992 with a doxorubicin-
containing regimen, while 20% received mechlorethamine,
oncovin, procarbazine, and prednisone (MOPP) or similar
regimens. By multivariate analysis, seven clinical parameters
were independently associated with a poorer outcome: male
sex, age > 45 years, clinical stage IV, hemoglobin < 10.5 g/dl,
WBC count > 15 × 109/L, lymphocyte count < 0.6 × 109/L or
8% of differential, and albumin < 4 g/dL [1]. In 2012, Moccia
et al. [2] evaluated individual IPS factors in 740 patients with
stage III/IV or stage I/II HL who had B symptoms or bulky
disease and were treated with adriamycin, bleomycin, vinblas-
tine, and dacarbazine (ABVD) or an ABVD-equivalent regi-
men with curative intent. In an analysis restricted to 686 pa-
tients aged ≤ 65 years, as in the original index, the IPS
remained prognostic for failure-free survival (FFS) and overall
survival (OS), but with a narrower range of outcomes, proba-
bly related to the improvement in survival outcomes in all risk
groups and mainly in the poorer-risk groups. Further, the re-
sults showed that all individual factors, with the exception of
gender, were prognostic in univariate analysis for FFS, but
only age and hemoglobin level maintained significance in
multivariate analysis. These results confirmed that IPS re-
mains prognostic in patients with advanced-stage HL, but
the range of outcomes delineated on the basis of the number
of factors present at diagnosis has significantly diminished. To
assess the utility of the individual IPS factors in the contem-
porary era, Diefenbach et al. [3] analyzed data from 854 pa-
tients with HL enrolled in the North American Intergroup trial,
E2496 [4]. The results of the study showed that the IPS
remained prognostic, but the separation between IPS groups
narrowed, confirming the results fromMoccia et al. [2]. Thus,
they proposed an alternative prognostic index, the IPS-3,
based only on 3 factors, age, stage, and hemoglobin level,
showing that this model outperformed the original IPS on risk
prediction for both FFS and OS. The aim of the present study
was to assess whether classic prognostic factors maintain their
prognostic meaning at the time of PET-guided treatment.
Material and methods
The HD0801 multicenter study [5] involved 520 patients with
histologically documented, advanced-stage HL (clinical stage
II B–IV) enrolled between September 2008 and April 2013 at
28 Italian centers. All patients received initial treatment with
ABVD. After 2 cycles of ABVD, an interim PET was
performed and 510 patients continued therapy according to
the experimental protocol. Patient showing negative PETafter
2 ABVD cycles (I-PET or PET2) recieved an additional 4
cycles of ABVD, while patients who were I-PET-positive
underwent an early intensification with 4 cycles of ifosfamide,
gemcitabine, and vinorelbine (IGEV) followed by carmustine,
cytarabine, etoposide, and melphalan (BEAM)–conditioned
autologous bone marrow transplantation. All local ethic com-
mittees at each center approved the study protocol and its
amendments in accordance with Italian law and in compliance
with the Declaration of Helsinki. Patients provided written
informed consent before being included in the study.
Absolute monocyte count (AMC) was not included in the
original electronic case report form (CRF), and 19 centers
agreed to add AMC to the initial patient CRFs
Statistical analysis
Progression-free survival (PFS) was defined as the time from
I-PET to the time of any documented progressive disease,
relapse, or death from any cause. Patient baseline characteris-
tics are expressed as absolute frequencies and percentages for
categorical variables. Continuous variables were reported as
the median and 2.5–97.5 percentiles. The Kaplan-Meier meth-
od was used to estimate PFS. Statistical comparisons by
groups of risk were performed with the log-rank test. As cut-
offs for AMC, neutrophil lymphocyte ratio (NLR)
and lymphocyte monocyte ratio (LMR), we utilized 0.75 ×
109/L, 6, and 2.1, respectively, as previously published [6, 7].
Results
The median age of the patients was 33 years and 54% were
male. Most of the patients (73%) had a nodular sclerosis sub-
type, and 46% presented with clinical stage IV disease. An
IPS ≥ 3 was observed in 43% of patients. The demographic
and baseline disease characteristics of the entire population are
listed in Table 1. After a median follow-up of 45 months, the
Kaplan-Meier estimates for the entire population were 97%
and 80% for OS and PFS, respectively. PET2-negative and
PET2-positive patients had a PFS of 81% and 74%, respec-
tively. Overall, 97 patients underwent disease progression, 21
and 73 in the PET2 positive and negative group, respectively,
and 18 patients died, 8 and 10 in PET2-positive and PET2-
negative group, respectively.
Outcome according to IPS and single factors
contributing to IPS
We analyzed separately all patients, PET2-negative patients,
and PET2-positive patients (Table 2). In the overall patient
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population, PFS according to IPS factors did not show statis-
tically significant differences related to IPS score nor to single
factors contributing to the IPS except for a significant differ-
ence related to hemoglobin level ≥ 10.5 g/dL observed in all
patients (P = 0.033) and in PET2-negative patients (P =
0.003), and related to low lymphocyte counts in PET2-
positive patients (P = 0.032). Instead, analyzing PET2-
positive patients, not even hemoglobin values < 10.5 g/dL,
discriminated patients with a worse PFS.
Outcome according to AMC, NLR, and LMR
In the 292 patients in which AMC was added to the original
CFR, we also evaluated the prognostic meaning of AMC,
NLR, and LMR. No statistically significant differences in PFS
were observed between 234 patients (80%) with a negative I-
PET and 58 patients (20%) with positive I-PET (P = 0.260). In
the overall population, patients with AMC ≤ or > 0.75 × 109/L,
NLR < 6 or ≥ 6, and LMR ≤ 2.1 or > 2.1 had similar PFS, with
no significant differences between groups (Table 3). Also, con-
sidering I-PET-positive and I-PET-negative patients separately,
AMC, NLR, and LMR did not show any predictive effect for
PFS. Further, AMC ≤ or > 0.75 × 109/L, NLR < 6 or ≥ 6, and
LMR ≤ 2.1 or > 2.1 at diagnosis were not associated with I-
PET results. In addition, different AMC, NLR, and LMR cutoff
points did not discriminate different prognostic groups in this
series.
Discussion
In the modern era, the classic IPS retains its prognostic capacity
in patients with advanced HL treated with ABVD. However, the
range of outcomes has considerably narrowed [2, 3]. This is
probably related to improvement in survival outcomes in high-
risk patients. Several reasons determine this improvement, in-
cluding the enhanced diagnostic accuracy, and the large avail-
ability of better supportive care and neutrophil growth factors. To
explore whether classic prognostic factors retain their meaning at
the time of PET-guided treatment, we analyzed the recently pub-
lished literature on this topic. The US Intergroup Trial of
response-adapted therapy [8] enrolled 358 patients with stage
III and IV HL in a phase II clinical trial. A PET scan (PET2)
was performed after two courses of ABVD. Patients with a
Deauville score 1 to 3 (PET2-negative) received an additional
4 ABVD cycles, while patients with a Deauville score of 4 and 5
(PET2-positive) were switched to an intensified regimen of
bleomycin, etoposide, doxorubicin, cyclophosmamide, vincris-
tine, procarbazine, and prednisone (escalated-dose
BEACOPP,eBEACOPP) for six courses. The PFS at 2 years
was 64% in PET2-positive patients switched to intensified treat-
ment. These results suggest an improvement in PFS for PET2-
positive patients compared with the historical experience with
continued ABVD. The risk of disease progression for PET2-
positive and for IPS high-risk patients were higher in comparison
with PET2-negative and IPS low-risk patients, but differences
were not statistically significant (P = 0.0442 and P = 0.2191,
respectively)
As expected, patients treated with eBEACOPP had much
more grade 4 and 5 adverse events than those who received
ABVD and three treatment-related death were observed, two
(4%) in the eBEACOPP and one (0.4%) in the ABVD arm.
Further, six patients developed secondary malignancies, includ-
ing three (1%) patients receiving ABVD and three (6.1%) in the
eBEACOPP arm.
Of note, 58 PET2-negative patients experienced treatment
failure, thus demonstrating that PET2 is not a completely reliable
test.
In another PET-guided treatment trial, Johnson et al. [9] eval-
uated 1214 patients with advanced HL. After 2 ABVD courses,
PET2-negative patients were randomized to receive 4 cycles of
ABVD versus 4 courses of AVD. PET2-positive patients were
randomized to receive BEACOPP 14 or eBEACOPP. PFS at 3
years for PET2-positive patients was 67.5%. An analysis of pos-
sible predictors of treatment failure was done only in subgroup of
patients who had PET2-negative scans. Initial Ann Arbor stage
was associated with the risk of disease progression, and the
Table 1 Baseline characteristics of the 510 patients who continued with
the experimental protocol after I-PET
N missing
IPS
0 4% (22)
1 21% (106)
2 32% (162)
≥3 43% (220)
Age, median (IQR) 33 (26–44)
Age ≥ 45y 24% (121)
Male 54% (275)
AA stage IV 46% (234)
Albumin ≥ 4 (g/dl) 57% (291)
HB (g/dl), median (IQR) 12.2
(11–13.5)
HB < 10.5 (g/dL) 16% (84)
WBC ≥ 15 × 109/L 30% (155)
Lymphocytes ≥ 0.6 × 109/L and ≥ 8%
WBC
13% (67)
PET2+ 20% (101)
ALC > 0.6 × 109/L 92% (464) 5
AMC > 0.75 × 109/L 48% (140) 218
NLR > 6 44% (222) 6
LMR ≤ 2.1 59% (169) 222
AA, Ann Arbour; HB, hemoglobin; WBC, white blood cells; ALC, abso-
lute lymphocyte count; AMC, absolute monocyte count; NLR, neutrophil
lymphocyte ratio; LMR, lymphocyte monocyte ratio
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differences among stage II versus III versus IV were statistically
significant. Although less strong, similar results were observed
for IPS.
Any grade 3 or 4 adverse events were reported in 69% of
patients who received 6 ABVD, in 65% of patients switched
on AVD, and 80–83% of patients in BEACOPP arms.
Overall, 19 (4.0%), 17 (3.6%), and 22 (12.8%) patients died
in the ABVD, AVD, and BEACOPP arm, respectively. Further,
13 (2.8%), 11 (2.4%), and 3 (1.74%) developed second cancer in
the ABVD, AVD, and BEACOPP arm, respectively.
The 3-years PFS in PET2-negative patients was 84.9% thus
confirming that continuing treatment with 4 additional ABVD
does not guarantee that patients have been cured.
The results of the GITIL/FIL HD 0607, another PET-guided
trial with a treatment schema similar to those of the US
Intergroup and Johnson trials, have been recently published
[10]. The 3-year PFS of PET2-positive patients assigned to
BEACOPP, with or without rituximab, was 60%. Evaluating
predictive factors of outcome, Gallamini et al. found that by
multivariate analysis, IPS was a predictive factor for a positive
PET2 scan and for PFS, but not for overall survival.
The most frequent toxicity was hematological, and it was
observed in 30% and 76% of patients in ABVD and
BEACOPP arm, respectively.
Among patients with PET2-positive and PET2-negative
results, 16 (11%) and 12 (2%) died respectively.
The 3-year PFS in PET2-negative patients was 82%. In
fact, a non-negligible proportion suffered disease recurrence,
confirming that PET2 is not a perfect technique in predicting
survival outcome.
In a retrospective study performed at a single institution
[11], the prognostic meaning of the ratio among lymphocytes,
neutrophils, andmonocytes was evaluated in newly diagnosed
patients with HL treated upfront with a PET2 risk-adapted
strategy, switching PET2-positive patients from ABVD to
the BEACOPP regimen for 8 cycles. PET2-positive patients
who were switched to BEACOPP had a PFS at 5 years of
40.1%. The IPS was unable to provide any clear distinction
in the outcomes for PFS, while NLR was prognostic for PFS
in univariate and, barely, in multivariate analysis.
Taken together, these results confirm that in the modern era
[2, 3], and particularly when the treatments were driven by the
results of PET2 [8–10], the IPS loses much of its prognostic
significance, by reducing the risk of progression in PET2-
positive patients. In all aforementioned studies [8–10], howev-
er, the intensification of therapy in PET2-positive patients was
made up with BEACOPP. Here, we evaluate the prognostic
significance of IPS in the PET-guided HD0801 trial. By
Table 2 Kaplan-Maier estimates of PFS from PET2 according to IPS components.
All patients PET2− PET2+
N 24-month PFS P N 24-month PFS P N 24-month PFS P
IPS 0 22 90.5% 0.257 19 94.4% 0.118 3 66.7% 0.490
1 106 79.6% 84 80.6% 22 75.0%
2 162 80.9% 130 83.5% 32 71.3%
≥ 3 220 77.6% 176 77.1% 44 79.1%
Age < 45 389 80.2% 0.118 305 81.6% 0.054 84 75.3% 0.888
≥ 45 121 77.6% 104 77.8% 17 76.5%
Gender Female 235 78.7% 0.770 187 80.3% 0.896 48 72.6% 0.715
Male 275 80.4% 222 80.9% 53 78.2%
Ann Arbor stage < IV 276 79.7% 0.356 225 82.1% 0.213 51 69.5% 0.551
IV 234 79.5% 184 78.9% 50 81.6%
Albumin ≥ 4 (g/dL) 219 82.3% 0.252 169 83.1% 0.275 50 79.6% 0.555
< 4 (g/dL) 291 77.6% 240 78.9% 51 71.3%
HB ≥ 10.5 (g/dL) 426 80.8% 0.033 340 82.7% 0.003 86 73.5% 0.385
< 10.5 (g/dL) 84 73.4% 69 70.4% 15 86.7%
WBC < 15 x 109/L 355 78.8% 0.836 292 80.3% 0.938 63 72.0% 0.563
≥ 15 x 109/L 155 81.4% 117 81.4% 38 81.3%
Lymphocytes ≥ 0.6 x 109/L and ≥ 8% WBC 443 80.4% 0.100 363 80.7% 0.743 80 79.4% 0.032
< 0.6 x 109/L or < 8% WBC 67 74.3% 46 80.3% 21 60.5%
All patients 510 79.6% 409 80.6% 101 75.6%
*P values were derived using log-rank test
HB, hemoglobin; WBC, white blood cells
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thoroughly analyzing the data, we observed that the IPS
completely loses its prognostic value together with all the single
parameters that contribute to the IPS. Neutrophils, monocytes,
lymphocytes, and the ratio among them also no longer had any
predictive value. A possible explanation for the complete loss
of meaning of the classic prognostic factors such as IPS, AMC,
LMR, and NLR could be the different therapy intensification
programs. While in all the aforementioned studies, the intensi-
fication was done with BEACOPP, in the HD0801 trial, the
intensification was performed by treating PET2-positive pa-
tients with 4 cycles of ifosfamide, gemcitabine, and vinorelbine
(IGEV) followed by carmustine, cytarabine, etoposide, and
melphalan (BEAM)–conditioned autologous bone marrow
transplantation. The final results of the phase II part of the
HD 0801 study showed that in PET2-positive patients, the
2-year PFS increased from 12% in the historical control to
74%, a slightly higher percentage than those reported in other
clinical trials after intensification with BEACOPP, ranging
from 60 to 67.5% [8–10]. While these results were obtained
in trials with different enrollment criteria, although all were
PET-guided, it could be hypothesized that early transplanta-
tion acts more thoroughly than BEACOPP in patients with
partial remission or stable disease after 2 cycles of ABVD.
The substantial improvement in survival outcomes in PET2-
positive patients could therefore explain the complete disap-
pearance of the residual prognostic significance of the IPS at
the time of PET-guided therapies.However, despite the im-
provements in survival outcomes observed in the HD0801
study, PET2-negative and PET2-positive patients still had a
PFS of 81% and 74%, respectively. Therefore, a considerable
fraction of patients remains at risk of relapse. In brief, the
results obtained in the four clinical trials are not substantially
different and show PFS between 81 and 85.7% in PET2-
negative patients and between 60% and 74% in PET2-
positive patients [5, 8–10]. Therefore, while a PET2-adapted
strategy can improve survival outcome in PET2-positive pa-
tients, a non-negligible proportion of about 20% of PET2-
negative patients remains at risk of relapse. Some patients
PET2-negative can progress or relapse as it happens to pa-
tients with follicular lymphoma that almost inexorably, after
a complete response (CR) will undergo a relapse, showing that
the metabolic response does not always correspond to the cure
of the disease. Furthermore, it is well established that a pro-
portion of PET2-positive patients can obtain CR while con-
tinuing on ABVD. Inflammation and tumor necrosis can
cause false positive interpretation of PET scan. Therefore, if
IPS is no longer able to predict outcomes at the time of PET-
guided treatment and if PET is a powerful tool, but not a
perfect one, it is essential to find new prognostic factors.
These parameters could be able to avoid over treatment in
false PET2-positive patients and to recognize PET2-negative
patients still at risk of progression/early relapse. Genetic pa-
rameters or new biomarkers or simply a technical/interpretive
improvement of PET scan are currently being evaluated. The
immune-suppressive component in HL microenvironment
evaluated by immunohistochemistry has a prognostic role
and seems able to improve the prognostic capabilities of
PET2 [12]. The gene expression profile has also been pro-
posed to be predictive of treatment failure [13, 14].
However, both immunohistochemical and genetic studies re-
quire prospective evaluation. Recently, some metabolic pa-
rameters as the valuation of total lesion glycolysis (TLG)
and metabolic tumor volume (MTV) [15] showed prognostic
value in patients with advanced stage cHL. Further in ad-
vanced disease, baseline TLG and MTV were significantly
associated with PET2 results and TLG was a robust predictor
of treatment failure and disease relapse [16]. The predictive
value of baseline MTV has also been showed in patients with
early stage cHL [17]. Recently, a gene expression–based score
has been proposed to predict PET2 positivity [18]. All these
methods offer strong promise for prognostication but require
further study and validation. Refining prognostication is cru-
cial as it represents a further step towards personalized medi-
cine, but so far it remains an issue.
Compliance with ethical standards
All local ethic committees at each center approved the study protocol and
its amendments in accordance with Italian law and in compliance with the
Declaration of Helsinki. Patients provided written informed consent be-
fore being included in the study.
Table 3 Kaplan-Maier estimates
of PFS from PET2 in patients
with absolute monocyte counts
(AMC) available
N 24-month PFS P
AMC ≤ 0.75 × 109/L 152 80.0% 0.760
> 0.75 × 109/L 140 81.7%
NLR ≤ 6 155 82.6% 0.260
> 6 134 78.2%
LMR > 2.1 119 78.5% 0.664
≤ 2.1 169 82.5%
All patients with available monocyte count 292 80.8%
*P values were derived using log-rank test
AMC, absolute monocyte count; NLR, neutrophil lymphocyte ratio; LMR, lymphocyte monocyte ratio
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